GLP-1 Prior Authorization: Get Approved (Or Win the Appeal)
Most commercial insurers require prior authorization (PA) before they will pay for Wegovy, Zepbound, Ozempic, or Mounjaro. The PA itself is not the problem — most denials happen because the submission is missing one of five documentation items. This page walks through what plans actually look for, what to do when you are denied, and how to file an appeal that works.
What every GLP-1 prior authorization needs
Plans differ in details, but the core five-item checklist is consistent across every major commercial payer (Aetna, BCBS, Cigna, UnitedHealthcare, Humana). If your PA is missing any of these, the most efficient path is to fix the gap before submitting — not appeal afterward.
- 1
A measured BMI ≥30 (or ≥27 with comorbidity)
Self-reported height/weight does not satisfy this. The chart note must show the BMI was measured in the office on a specific date, ideally within the last 6 months.
- 2
At least one weight-related comorbidity with ICD-10 code
Hypertension (I10), type 2 diabetes (E11.9), dyslipidemia (E78.5), obstructive sleep apnea (G47.33), and established CV disease are the most commonly accepted. Without a coded comorbidity, BMI 27–29.9 PAs are denied automatically.
- 3
Documented diet/exercise attempts (≥6 months)
A chart note saying 'patient has tried diet and exercise' is not enough. Plans want specifics: structured program name, dates, weight delta, why it failed. Weight Watchers, Noom, MyFitnessPal logs, supervised nutrition counseling — any of these counts if dated.
- 4
Baseline labs (HbA1c, lipid panel)
Labs serve two purposes: confirm the comorbidity is real, and establish a baseline so a follow-up PA renewal has data to show the drug is working.
- 5
Any prior weight-loss medications tried and failed
Phentermine, Contrave, Saxenda, Qsymia — if you have tried any, list them with dates and reason for discontinuation. Plans generally want to see at least one prior AOM trial before approving a brand-name GLP-1 unless your BMI is high enough to justify skipping step therapy.
If denied: a four-step appeal playbook
Roughly 30–50% of GLP-1 PA denials are reversed on appeal, and that number rises sharply when the appeal addresses the specific denial reason rather than just resubmitting the same packet. Move quickly — most plans set a 60-day clock from the denial letter.
- 1
Read the denial letter to identify the exact reason
Plans use specific codes: 'criteria not met', 'step therapy required', 'plan exclusion', or 'investigational/experimental'. Each requires a different response. Plan exclusion is the only one with no appeal path — everything else is appealable.
- 2
Request a peer-to-peer (P2P) review
Your prescriber requests a phone call with the plan's medical director. P2Ps reverse a meaningful percentage of denials because the plan-side reviewer often missed clinical context. This is the fastest path — typically 1–3 business days.
- 3
File a formal written appeal with new documentation
If the P2P fails (or your prescriber will not do one), file a written appeal that addresses the denial reason point-by-point and includes anything missing: updated BMI, additional comorbidity diagnoses, lab results, prior medication history. Include relevant FDA labeling and clinical guidelines (ACE/AACE 2023, AHA 2023 obesity statement) where they support your case.
- 4
External/independent review
If the internal appeal fails, you have the right to an external review by an independent third-party reviewer assigned through your state insurance commissioner. This is a federal right under the ACA for most plans. Self-funded ERISA plans have their own external-review process. Filing windows are typically 60–180 days after the final internal denial.
If your plan excludes weight-loss drugs entirely
Plan exclusions are not appealable. Three workable paths if you hit one:
- Switch to a covered indication. If you have type 2 diabetes, Ozempic (semaglutide) or Mounjaro (tirzepatide) are typically covered. They are the same molecules as Wegovy/Zepbound at comparable doses.
- Use cash-pay paths. NovoCare self-pay, LillyDirect, and telehealth (Hims/Ro/Lemonaid) bring monthly cost to ~$200–$500 — see Wegovy without insurance and Zepbound without insurance.
- Switch carriers at open enrollment. Most major employer plans now offer at least one option that covers AOM. Ask HR for the formulary list.
By insurer
PA criteria and approval rates vary significantly by carrier. Detailed pages for each major payer:
Frequently asked questions
Why does insurance require a prior authorization for GLP-1 drugs?+
GLP-1 drugs are expensive (list price $1,000–$1,400/month) and high-volume, so payers require a clinical paper trail before they pay. The PA process verifies you meet the plan-specific criteria — typically a BMI threshold, a comorbidity, prior weight-loss attempts, and a covered indication (type 2 diabetes for Ozempic/Mounjaro, chronic weight management for Wegovy/Zepbound). Without a PA, the pharmacy will reject the claim at the counter even if the prescription is valid.
What BMI is required for Wegovy or Zepbound prior authorization?+
Most commercial plans use the FDA label as the floor: BMI ≥30, OR BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Some plans require a higher threshold (BMI ≥35) or a longer documented history of obesity. Check your specific plan formulary — every payer publishes a Wegovy/Zepbound criteria document.
What documentation should my doctor include in the prior authorization?+
Five things move the needle most: (1) your most recent measured BMI with a date stamp, (2) one or more weight-related comorbidities with ICD-10 codes, (3) at least 6 months of documented diet/exercise attempts, (4) baseline labs (HbA1c, lipid panel) showing the comorbidity is real, and (5) any prior weight-loss medications you have tried and failed. Many denials are reversed when the appeal includes the ICD-10 code that was missing the first time.
How long does a GLP-1 prior authorization take?+
Standard turnaround is 24–72 hours for commercial insurance once the PA is submitted. Medicare Advantage and Medicaid plans can take 7–14 days. If you need it faster — for example, you are starting a structured weight-management program with a deadline — your doctor can request an "expedited review" which is supposed to come back within 72 hours. Pharmacies cannot speed this up; only the prescriber can submit and follow up.
My GLP-1 prior authorization was denied. What do I do?+
You have three layers of recourse: (1) ask your prescriber to file a peer-to-peer review where the doctor speaks directly to the plan medical director, (2) file a formal written appeal with additional clinical documentation (this reverses 30–50% of denials in most plans), and (3) escalate to an external/independent review through your state insurance commissioner if the internal appeal fails. Each level has a deadline — typically 60–180 days from the denial — so move quickly.
What are the most common reasons GLP-1 prior authorizations get denied?+
In rough order: (1) BMI documentation missing or below threshold, (2) no documented comorbidity with ICD-10 code, (3) no documented prior weight-loss attempts (diet/exercise for ≥6 months), (4) plan excludes weight-loss drugs entirely (an exclusion you cannot appeal — only switch carriers can fix this), and (5) prescription coded for an indication the plan does not cover (e.g., Ozempic prescribed off-label for weight loss when the plan only covers it for type 2 diabetes).
My plan excludes weight-loss drugs entirely. Am I stuck?+
You have three options. (1) Switch to a drug your plan does cover for a different indication — Ozempic and Mounjaro are covered as type 2 diabetes drugs and have the same molecule as Wegovy/Zepbound respectively. This is "off-label" prescribing and only works if you actually qualify for the diabetes indication. (2) Use cash-pay paths (NovoCare self-pay, LillyDirect, telehealth) which we cover on /wegovy-without-insurance and /zepbound-without-insurance. (3) Switch insurance during open enrollment to a plan that covers AOM (anti-obesity medications) — most major employers offer at least one option that does.
Does Medicare cover GLP-1 prior authorizations?+
Medicare Part D does not cover drugs prescribed solely for weight loss — this includes Wegovy and Zepbound when the indication is obesity. Medicare DOES cover Ozempic and Mounjaro for type 2 diabetes (with PA). In 2024 CMS expanded coverage of Wegovy specifically for cardiovascular risk reduction in patients with established CV disease and obesity (BMI ≥27); that requires a different PA pathway and a documented MI, stroke, or PAD history. Outside that narrow indication, expect a denial under Medicare.